Management of Bone Disease and Body Composition Changes
Summary
- Several studies have explored the efficacy of switching from a thymidine analogue NRTI to an alternative NRTI to try to reverse lipoatrophy[Moreno 2009]
- RAVE study[Moyle 2006] demonstrated that lipid changes were significantly more favorable in patients switched to tenofovir DF vs those switched to abacavir
- SWEET study[Fisher 2009] showed a modest increase in limb fat that tended toward significance in patients who switched to emtricitabine/tenofovir DF from lamivudine/zidovudine, and those who continued lamivudine/zidovudine experienced further decreases in limb fat
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content